

Prophylactic **TRE**atment **O**f the du**C**tus **A**rteriosus in **P**reterm infants by **A**cetaminophen

Dear investigators, dear all,

We reached **500 / 794** patients in mid-April !

In March the rate of inclusion was **32** inclusions in a month. Thank you all for your involvement !

TREOCAPA'S LATEST NEWS :




1. Phase II results paper

The writing of the Treocapa phase II results paper has been finished, after the co-authors review. It is now ready for submission, we will keep you updated once published.

2. The mid-term Interim Analysis

The last visit of the last patient in the interim analysis was at the end of April.

To conduct the analysis we need **all** patient records belonging to the analysis to be **completed** as much as possible and **locked**.



Actual total percentage of completed and locked pages on the eCRF

3. Meeting with sites in difficulties

The coordination team is continuing meetings with sites experiencing difficulties with inclusions. Recently, a discussion with investigators from Quironsalud and San Carlos sites allowed for reassurance of the teams, to answer their questions and to find solutions together.

4. Factsheet by EFCNI

EFCNI, our public and patient involvement partner, designed a factsheet for parents and caregivers to raise awareness on the importance of clinical trials in newborns using the TREOCAPA study as an example. The factsheet is available [here](#) on EFCNI's website.

TREOCAPA is a study co-developed with parents and their European representatives.

This study is funded by the c4c project. Find out more here: <https://conect4children.org/>